Abstract:Background: CaMKII (Ca2+/calmodulin-dependent kinase II) plays a central role in cardiac ischemia/reperfusion (I/R) injury-an important therapeutic target for ischemic heart disease. In the heart, CaMKII-delta is the predominant isoform and further alternatively spliced into 11 variants. In humans, CaMKII-delta 9 and CaMKII-delta 3, the major cardiac splice variants, inversely regulate cardiomyocyte viability with the former pro-death and the latter pro-survival. However, it is unknown whether specific inhibition of the detrimental CaMKII-delta 9 prevents cardiac I/R injury and, if so, what is the underlying mechanism. Here, we aim to investigate the cardioprotective effect of specific CaMKII-delta 9 inhibition against myocardial I/R damage and determine the underlying mechanisms. Methods: The role and mechanism of CaMKII-delta 9 in cardiac I/R injury were investigated in mice in vivo, neonatal rat ventricular myocytes, and human embryonic stem cell-derived cardiomyocytes. Results: We demonstrate that CaMKII-delta 9 inhibition with knockdown or knockout of its feature exon, exon 16, protects the heart against I/R-elicited injury and subsequent heart failure. I/R-induced cardiac inflammation was also ameliorated by CaMKII-delta 9 inhibition, and compared with the previously well-studied CaMKII-delta 2, CaMKII-delta 9 overexpression caused more profound cardiac inflammation. Mechanistically, in addition to IKK beta (inhibitor of NF-kappa B [nuclear factor-kappa B] kinase subunit beta), CaMKII-delta 9, but not delta 2, directly interacted with I kappa B alpha (NF-kappa B inhibitor alpha) with its feature exon 13-16-17 combination and increased I kappa B alpha phosphorylation and consequently elicited more pronounced activation of NF-kappa B signaling and inflammatory response. Furthermore, the essential role of CaMKII-delta 9 in myocardial inflammation and damage was confirmed in human cardiomyocytes. Conclusions: We not only identified CaMKII-delta 9-IKK/I kappa B-NF-kappa B signaling as a new regulator of human cardiomyocyte inflammation but also demonstrated that specifically targeting CaMKII-delta 9, the most abundant CaMKII-delta splice variant in human heart, markedly suppresses I/R-induced cardiac NF-kappa B activation, inflammation, and injury and subsequently ameliorates myocardial remodeling and heart failure, providing a novel therapeutic strategy for various ischemic heart diseases.

Rescue of cardiac failing and remodelling by inhibition of protein phosphatase 1γ is associated with suppression of the alternative splicing factor-mediated splicing of Ca2+/calmodulin-dependent protein kinase δ.

PP1γ Functionally Augments the Alternative Splicing of CaMKIIδ Through Interaction with ASF

Inhibition of TRPC1 Prevents Cardiac Hypertrophy Via NF-κB Signaling Pathway in Human Pluripotent Stem Cell-Derived Cardiomyocytes.

Phosphatase PPM1L Prevents Excessive Inflammatory Responses and Cardiac Dysfunction after Myocardial Infarction by Inhibiting IKKβ Activation.

Inhibition of Farnesyl Pyrophosphate Synthase Improves Pressure Overload Induced Chronic Cardiac Remodeling

[Role of Bcl-2 Transcriptional Regulation Induced by Calmodulin I Pressure Overload Rat Hypertrophic Hearts].

Activation of Peroxisome Proliferator-Activated Receptor γ (PPARγ) Through NF-κB/Brg1 and TGF-ß1 Pathways Attenuates Cardiac Remodeling in Pressure-Overloaded Rat Hearts

Relationship between HSPA1A-regulated gene expression and alternative splicing in mouse cardiomyocytes and cardiac hypertrophy

Effects of PP1-12, a novel protein phosphatase-1 inhibitor, on ventricular function and remodeling after myocardial infarction in rats.

Peroxisome proliferator–activated receptor gamma coactivator 1 alpha protects cardiomyocytes from hypertrophy by suppressing calcineurin-nuclear factor of activated T cells c4 signaling pathway

Protein Phosphatase 2A Effectively Modulates Basal L-type Ca2+ Current by Dephosphorylating Cav1.2 at Serine 1866 in Mouse Cardiac Myocytes

Integrative Physiology Role of Ca /Calmodulin–Stimulated Cyclic Nucleotide Phosphodiesterase 1 in Mediating Cardiomyocyte Hypertrophy

Cardioprotection by CaMKII-δB is Mediated by Phosphorylation of Heat Shock Factor 1 and Subsequent Expression of Inducible Heat Shock Protein 70

Abstract 9615: PP1-12, a Novel Protein Phosphatase-1 Inhibitor, Ameliorates Ventricular Function after Myocardial Infarction in Rats

Signal Transducer and Transcriptional Activation 1 Protects Against Pressure Overload‐induced Cardiac Hypertrophy

Caspase-1 Abrogates the Salutary Effects of Hypertrophic Preconditioning in Pressure Overload Hearts Via IL-1β and IL-18.

Targeting CaMKII-9 Ameliorates Cardiac Ischemia/Reperfusion Injury by Inhibiting Myocardial Inflammation

Ca2+/Calmodulin-Dependent Protein Kinase II Regulation by Inhibitor of RIPK3 Protects Against Cardiac Hypertrophy

Up-regulation of Paired-Related Homeobox 2 Promotes Cardiac Fibrosis in Mice Following Myocardial Infarction by Targeting of Wnt5a.

Abstract 408: Spliced X-box Binding Protein 1 Promotes Cardiac Hypertrophy Through Activation of Mtorc1

Β-Adrenergic Activation May Promote Myosin Light Chain Kinase Degradation Through Calpain in Pressure Overload-Induced Cardiac Hypertrophy: Β-Adrenergic Activation Results in MLCK Degradation.